Tissue Based Genomic Profiling Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Technology (Sequencing Techniques, Immunohistochemistry, Others), By Application (Personalized Medicine, Oncological Diagnostics, Research), By End-User (Research Institutes, Clinical Research Organizations, Hospitals & Clinics, Diagnostic Laboratories, Pharmaceutical & Biotechnology Companies, Others), By Region and Competition, 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 1.52 Billion
CAGR (2026-2031)	6.76%
Fastest Growing Segment	Sequencing Techniques
Largest Market	North America
Market Size (2031)	USD 2.25 Billion

Market Overview

The Global Tissue Based Genomic Profiling Market will grow from USD 1.52 Billion in 2025 to USD 2.25 Billion by 2031 at a 6.76% CAGR. The Global Tissue Based Genomic Profiling Market encompasses diagnostic technologies that analyze tumor tissue samples to detect specific genomic alterations, such as mutations and copy number variations, which guide the selection of targeted therapies. A primary driver supporting this market is the escalating incidence of cancer worldwide, necessitating precise molecular characterization to facilitate personalized medicine. Additionally, the increasing regulatory approval of companion diagnostics and the integration of genomic data into clinical decision-making significantly bolster market growth. According to the American Cancer Society, in 2024, it was projected that new cancer cases in the United States would exceed 2 million for the first time, distinguishing the urgent demand for accurate diagnostic capabilities.

Despite this favorable trajectory, one significant challenge impeding market expansion is the high cost of comprehensive genomic testing coupled with inconsistent reimbursement policies across different healthcare systems. These financial barriers often restrict patient access and delay the routine adoption of these diagnostic tests in community oncology settings. Furthermore, the reliance on invasive biopsies to obtain sufficient high-quality tissue samples presents a logistical obstacle, as inadequate sample quantity or quality can lead to test failure and hinder the successful execution of genomic assays.

Key Market Drivers

Rapid advancements in Next-Generation Sequencing (NGS) technologies act as a cornerstone for the Global Tissue Based Genomic Profiling Market by enhancing the throughput, accuracy, and affordability of tumor analysis. The shift from single-gene testing to comprehensive genomic profiling (CGP) is largely fueled by the deployment of high-capacity sequencing platforms that allow laboratories to process vast amounts of tissue data efficiently. This technological leap enables clinicians to identify rare alterations and complex signatures, such as Tumor Mutational Burden (TMB), that were previously undetectable with standard methods. Evidence of this accelerated adoption is visible in the industrial sector; according to Illumina, February 2024, in the 'Fourth Quarter and Fiscal Year 2023 Financial Results', the company shipped 352 of its advanced NovaSeq X instruments during the fiscal year 2023, signaling a robust upgrade cycle in genomic laboratories globally.

The growing adoption of precision medicine and the expansion of biomarker-driven drug development pipelines further propel market demand, as therapeutic efficacy increasingly depends on specific molecular diagnoses. Biopharmaceutical companies are prioritizing the development of targeted therapies that require companion diagnostics to identify eligible patients, thereby embedding genomic profiling into standard clinical workflows. This trend is underscored by regulatory milestones; according to the Personalized Medicine Coalition, February 2024, in the 'Personalized Medicine at FDA: The Scope & Significance of Progress in 2023' report, personalized medicines accounted for more than one-third of all new drug approvals for the fourth consecutive year in 2023. This reliance on biomarker-guided treatment directly translates into commercial growth for diagnostic providers. According to Exact Sciences, in 2024, the company generated $629 million in revenue specifically from its Precision Oncology segment during the previous year, reflecting the critical economic role of tissue-based genomic testing in modern cancer care.

Download Free Sample Report

Key Market Challenges

The high cost of comprehensive genomic testing coupled with inconsistent reimbursement policies serves as a substantial barrier to the expansion of the Global Tissue Based Genomic Profiling Market. When insurance payers frequently deny coverage or provide reimbursement that falls below the operational cost of performing these complex assays, clinical laboratories face severe financial pressure. This economic uncertainty discourages community oncology practices from routinely ordering broad genomic profiles, effectively limiting the market's reach to well-funded academic centers. Consequently, the volume of tests performed remains lower than the clinical demand, directly stifling revenue generation and slowing the overall adoption of precision medicine tools.

This financial instability significantly hampers the operational capacity of diagnostic providers, forcing them to make difficult resource allocation decisions. According to the College of American Pathologists, in 2024, 72% of pathology practice leaders reported being negatively impacted by declining reimbursement rates over the past five years. Such fiscal constraints compel laboratories to reduce staffing or limit their test menus, which can lead to increased turnaround times and reduced service availability. These operational bottlenecks, driven by adequate payment mechanisms, prevent the market from scaling efficiently to meet the rising global burden of cancer.

Key Market Trends

The integration of Artificial Intelligence (AI) for genomic data interpretation is transforming the Global Tissue Based Genomic Profiling Market by automating the analysis of massive NGS datasets. Laboratories are increasingly relying on AI algorithms to accelerate variant annotation and identify actionable biomarkers that manual analysis might overlook. This convergence enables the rapid scaling of precision oncology, making data-driven clinical decision support indispensable for handling the complexity of comprehensive profiles. According to Tempus AI, May 2024, in its 'Form S-1 Registration Statement', the company reported revenue of $532 million for the fiscal year 2023, a 66% increase over the previous year, highlighting the growing demand for AI-enabled precision medicine solutions.

Simultaneously, the emergence of multi-omics profiling combining DNA and RNA analysis is providing a holistic view of the tumor microenvironment. This trend extends beyond simple mutation detection to encompass gene expression signatures, offering deeper insights into tumor heterogeneity and therapeutic resistance mechanisms. Researchers and clinicians are leveraging these advanced tools to refine patient stratification for immunotherapies, driving significant investment in spatial biology technologies. This shift is substantiated by notable financial growth; according to 10x Genomics, February 2024, in the 'Fourth Quarter and Full Year 2023 Financial Results', the company achieved full-year revenue of $618.7 million, a 20% increase from 2022, driven by the adoption of its spatial and single-cell profiling instruments.

Segmental Insights

The Sequencing Techniques segment currently demonstrates the most rapid expansion within the Global Tissue Based Genomic Profiling Market. This accelerated growth is fundamentally driven by the rising clinical preference for Next-Generation Sequencing over single-gene assays, as it allows for the simultaneous analysis of multiple genomic alterations. Furthermore, the United States Food and Drug Administration has increasingly granted approval for sequencing-based companion diagnostics, which solidifies their role in guiding targeted therapy decisions. Consequently, the ability of these techniques to support precision medicine initiatives continues to fuel their dominant market trajectory.

Regional Insights

North America maintains the leading position in the Global Tissue Based Genomic Profiling Market due to the high adoption rate of precision oncology and the strong presence of major biotechnology firms. The dominance of this region is supported by substantial healthcare spending and a favorable regulatory framework, exemplified by the U.S. Food and Drug Administration granting approvals for various companion diagnostic tests. Furthermore, comprehensive reimbursement coverage for genomic testing services encourages clinical integration. These factors combined with established research infrastructure drive the continuous expansion of the market throughout the United States and Canada.

Recent Developments

• In August 2024, Illumina received approval from the U.S. Food and Drug Administration for its TruSight Oncology Comprehensive test. This in vitro diagnostic kit interrogates over 500 genes to profile solid tumors, identifying clinically actionable biomarkers and immuno-oncology signatures. The approval established the test as a distributable, comprehensive genomic profiling solution with pan-cancer companion diagnostic claims. This development enables laboratories to perform advanced tissue-based testing in-house, facilitating the matching of patients with rare gene fusions to appropriate targeted therapies.
• In June 2024, Labcorp announced the launch of "Labcorp Tissue Complete", a comprehensive genomic profiling service available for research and investigational use. The service, powered by the PGDx elio tissue complete assay, was expanded to the company's laboratories in Geneva and Shanghai to support global clinical trials. This offering aims to standardize biomarker-directed patient testing across multiple sites, reducing data variability and improving logistical efficiencies for biopharmaceutical partners. The expansion facilitates broader access to advanced tissue-based genomic analysis for the development of precision oncology therapies.
• In May 2024, QIAGEN launched the QIAseq Multimodal DNA/RNA Library Kit, a new solution designed to facilitate multiomic studies and comprehensive genomic profiling. The kit enables the simultaneous preparation of DNA and RNA libraries from a single sample, including formalin-fixed paraffin-embedded (FFPE) tissues, which are widely used in cancer research. This product advancement addresses the need for efficient workflows in precision medicine, allowing researchers to generate high-quality genomic data from limited and challenging tissue samples to identify potential biomarkers and therapeutic targets.
• In March 2024, Thermo Fisher Scientific announced a collaboration with Bayer to develop next-generation sequencing-based companion diagnostic assays. The partnership focuses on utilizing the Oncomine Dx Express Test on the Ion Torrent Genexus Dx System to identify patients who may benefit from precision cancer therapies. This initiative aims to provide decentralized genomic testing with rapid turnaround times for both tumor tissue and liquid biopsy samples, thereby expanding patient access to targeted treatments and supporting the development of personalized oncology regimens.

Key Market Players

• Foundation Medicine Inc
• Illumina, Inc.
• QIAGEN N.V.
• Roche Diagnostics Corp
• Thermo Fisher Scientific Inc.
• Exact Sciences Corp
• Personal Genome Diagnostics Inc.

By Technology	By Application	By End-User	By Region
Sequencing Techniques Immunohistochemistry Others	Personalized Medicine Oncological Diagnostics Research	Research Institutes Clinical Research Organizations Hospitals & Clinics Diagnostic Laboratories Pharmaceutical & Biotechnology Companies Others	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Tissue Based Genomic Profiling Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Tissue Based Genomic Profiling Market, By Technology:

• Sequencing Techniques
• Immunohistochemistry
• Others

• Tissue Based Genomic Profiling Market, By Application:

• Personalized Medicine
• Oncological Diagnostics
• Research

• Tissue Based Genomic Profiling Market, By End-User:

• Research Institutes
• Clinical Research Organizations
• Hospitals & Clinics
• Diagnostic Laboratories
• Pharmaceutical & Biotechnology Companies
• Others

• Tissue Based Genomic Profiling Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE